Allergy Shots: How Long to Work? Response Times by Allergen Type

Grass pollen allergy shots typically produce noticeable improvement during the first treatment-overlapping pollen season, usually 3-6 months after reaching maintenance dose. Because grass pollen season is clearly defined (spring through early summer in most US regions), patients can directly compare their symptom burden before versus during treatment. Calderon et al. (Cochrane 2007) found nasal symptom scores improved by 29-32% and medication use by 32-41% at the peak-dose level in randomized controlled trials. The large UK Immunotherapy Study Group trial (Frew et al., JACI 2006, n=410) showed symptom score reductions of 29% and medication reductions of 32% at full-season analysis. Most grass-sensitized patients notice a clearly better hay fever season within 1-2 years of starting treatment.

Dust mite allergy shots typically show significant symptom reduction at 12 months in controlled trial data, though some patients notice gradual improvement earlier. Because dust mite exposure is perennial (year-round), improvement is harder to detect in a defined 'season' and tends to manifest as a general reduction in baseline symptoms — less morning congestion, fewer antihistamine doses, better sleep quality. Abramson et al. (Cochrane 2010, CD001186) found symptom score SMD of -0.95 for HDM-driven perennial rhinitis, with dust mite contributing the bulk of perennial AR evidence. Longer treatment duration is associated with better outcomes: Lee et al. (Allergy Asthma Immunol Res 2018) found treatment duration of 3+ years was the strongest predictor of clinical remission in HDM-SCIT patients (OR 7.37).

Cat dander allergy shots take longer to produce meaningful improvement — typically 6-18 months — because most cat-allergic patients live with or regularly visit cats, meaning continuous high allergen exposure partially undermines the desensitization process throughout treatment. Each injection is training the immune system to tolerate cat allergen while the patient's home environment is simultaneously re-exposing them to high cat allergen loads (Fel d 1 is a particularly sticky, airborne protein that persists in homes for months). Varney et al. (Clin Exp Allergy 1997) demonstrated that the 15 µg Fel d 1 maintenance dose consistently produces significant improvement, but the timeline requires patience. Reducing home cat allergen burden during treatment — HEPA air purifiers, keeping cats out of bedrooms — can improve response speed.

Cluster and rush protocols compress the build-up phase timeline significantly but do not accelerate the biological immune response to the allergen. Standard build-up reaches maintenance in 3-6 months with weekly injections. Cluster protocols achieve maintenance in approximately 4-8 weeks with 2-3 injections per visit on non-consecutive days (Calabria, Ann Allergy Asthma Immunol 2023). Rush protocols complete build-up in 1-3 days under hospital monitoring. Because symptom improvement follows maintenance dose achievement, faster build-up means patients may notice improvement sooner in calendar time — but the underlying immune changes still require 3-6 months of adequate maintenance dosing before clinical benefit registers. Cluster and rush carry higher per-injection systemic reaction rates than conventional build-up.

Multi-allergen SCIT may produce slower or less robust improvement than single-allergen treatment, particularly when the mix contains more than two or three unrelated allergens. Nelson's review (JACI 2009) found evidence for efficacy with two-allergen mixes but inconsistent results for mixes of three or more allergens, attributing this to per-component dose dilution — each allergen gets a smaller share of the therapeutic dose. The European approach of single-allergen SCIT avoids this dilution problem but requires multiple separate treatment courses for polysensitized patients. US practice typically uses multi-allergen mixes as a pragmatic compromise. If response is slower than expected, your allergist may consider simplifying the mix or prioritizing the most clinically relevant allergen.

If allergy shots show no benefit after 12 months at an adequate maintenance dose, the AAAAI/ACAAI Practice Parameter recommends considering discontinuation unless there are identifiable correctable factors. Non-response at 12 months affects approximately 10-20% of SCIT patients. Before concluding failure, allergists typically reassess whether: (1) the allergen selection matches the patient's actual clinical triggers (skin testing vs. symptom correlation); (2) the maintenance dose contains adequate major allergen per dose (5-20 micrograms for inhalant allergens); (3) environmental controls have been optimized; and (4) adherence has been consistent. Month-12 clinical response strongly predicts 24-month outcomes (AUC 0.860 in predictive modeling), so genuine lack of response at this milestone is a meaningful signal.